AbbVie Inc. (NYSE:ABBV) Shares Sold by Sound Income Strategies LLC

Sound Income Strategies LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBVFree Report) by 1.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 115,352 shares of the company’s stock after selling 2,163 shares during the quarter. AbbVie makes up about 1.6% of Sound Income Strategies LLC’s portfolio, making the stock its 17th biggest position. Sound Income Strategies LLC’s holdings in AbbVie were worth $15,541,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Kalos Management Inc. acquired a new stake in AbbVie during the 1st quarter worth about $26,000. Boulder Wealth Advisors LLC purchased a new stake in shares of AbbVie in the fourth quarter worth approximately $31,000. Stone House Investment Management LLC acquired a new stake in shares of AbbVie during the first quarter worth approximately $37,000. True Wealth Design LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $39,000. Finally, General Partner Inc. acquired a new position in AbbVie in the 1st quarter valued at approximately $40,000. Institutional investors and hedge funds own 67.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ABBV shares. Piper Sandler upped their price target on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. TheStreet upgraded AbbVie from a “c+” rating to a “b” rating in a report on Monday, August 28th. William Blair started coverage on AbbVie in a report on Tuesday, July 25th. They issued a “market perform” rating on the stock. began coverage on shares of AbbVie in a research report on Thursday, August 17th. They issued a “strong-buy” rating for the company. Finally, HSBC began coverage on shares of AbbVie in a report on Friday, July 14th. They set a “buy” rating and a $167.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.79.

Check Out Our Latest Stock Report on ABBV

AbbVie Trading Down 1.0 %

AbbVie stock opened at $152.09 on Friday. The business’s 50-day simple moving average is $146.09 and its 200-day simple moving average is $147.56. AbbVie Inc. has a 52 week low of $130.96 and a 52 week high of $168.11. The firm has a market capitalization of $268.45 billion, a PE ratio of 31.29, a PEG ratio of 2.74 and a beta of 0.58. The company has a debt-to-equity ratio of 4.33, a quick ratio of 0.77 and a current ratio of 0.89.

AbbVie (NYSE:ABBVGet Free Report) last issued its quarterly earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.79 by $0.12. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. The company had revenue of $13.87 billion for the quarter, compared to the consensus estimate of $13.52 billion. Equities research analysts forecast that AbbVie Inc. will post 11.03 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a $1.48 dividend. The ex-dividend date is Thursday, October 12th. This represents a $5.92 annualized dividend and a yield of 3.89%. AbbVie’s dividend payout ratio is 121.81%.

Insider Transactions at AbbVie

In related news, CEO Richard A. Gonzalez sold 18,500 shares of AbbVie stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the sale, the chief executive officer now directly owns 625,294 shares of the company’s stock, valued at $93,262,600.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.26% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.